
|Articles|February 15, 2004
New drug application sought for combination IOP medication
Alcon is asking the FDA to approve a new drug application for its travoprost 0.004% plus timolol 0.5% fixed combination (TTFC) for the reduction of IOP in the treatment of glaucoma.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Beyond the surface: Tackling complex dry eye cases
3
Redefining glaucoma care: Where innovation meets clinical insight
4
An Extreme Case of Demodex Blepharitis: From Misdiagnosis to Remarkable Recovery
5



















































.png)


